GlaxoSmithKline has gained an ally in its push to accelerate drug discovery by collaborating on the application of computational biology to target validation. The ally, Biogen, is the first firm to join the initiative since GSK set it up in collaboration with the Wellcome Trust Sanger Institute and the European Bioinformatics Institute in 2014.
GlaxoSmithKline's flu vaccines, Fluarix and FluLaval, are both egg-based and can take months to produce each year. Now, the company has signed a pair of research deals, one of which would allow it to make cell-based vaccines, which are more efficient to manufacture.
Some of GlaxoSmithKline's prominent investors may be pushing for a four-way breakup of the company. But others are just fine preserving the status quo--and keeping CEO Andrew Witty at the helm to do it.
Biogen has signed up with a GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.
Not every market has been enthusiastic about slow-starting GlaxoSmithKline respiratory newcomer Anoro. But the company has been offering doctors another option, too--and it's starting to pay off.
GlaxoSmithKline saw another sharp drop in China sales of established pharmaceuticals, but CEO Andrew Witty said that was all part-and-parcel of reshaping the business including sales of products in the Middle Kingdom and that 2016 should start to see a turnaround, along with emerging markets generally.
Thanks to flailing pharma revenues and its decision to ship away its oncology assets, GlaxoSmithKline has a lot riding on vaccines. And in 2015, the unit delivered with 19% revenue growth, although profit and operating margin both fell.
GlaxoSmithKline CEO Andrew Witty is running out of ways to say it: A spinoff of the consumer health joint venture it shares with Novartis just isn't happening right now.
All 69 of the United States' National Cancer Institute-designated centers have joined together to issue a statement urging an increase in HPV vaccinations, declaring the vaccines "tragically underused" and calling low uptake a "public health threat."
As the global alarm continues to sound about the Zika virus, Sanofi said on Tuesday that it's getting involved. In doing so, it became the first major pharmaceutical company to get involved in the Zika vaccine race, launching a program to develop a jab just after receiving the first regulatory approvals for its dengue shot.